Literature DB >> 20061033

Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge.

Joan B O'Sullivan1, Karen M Ryan, Andrew Harkin, Thomas J Connor.   

Abstract

Evidence suggests that noradrenaline has a tonic anti-inflammatory action in the central nervous system (CNS) via its ability to inhibit expression of inflammatory mediators from glial cells. Consequently it is suggested that noradrenaline may play an endogenous neuroprotective role in CNS disorders where inflammatory events contribute to pathology. Infiltration of peripheral immune cells into the brain is driven by increased chemokine and cell adhesion molecule (CAM) expression, and is known to exacerbate neuroinflammation and thereby contribute to the disease process in a number of neurodegenerative disease states. Here we demonstrate that treatment of rats with the noradrenaline reuptake inhibitors (NRIs) desipramine and atomoxetine, agents that increase extracellular noradrenaline in the CNS, suppressed chemokine and cell adhesion molecule (CAM) expression in rat brain following a systemic challenge with bacterial lipopolysaccharide (LPS). Specifically, these agents reduced expression of the chemokines, interferon-inducible protein-10 (IP-10, CXCL-10) and regulated upon activation normal T-cell expressed and secreted (RANTES, CCL-5), and the CAMs, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule (ICAM-1) in cortex and hippocampus. The inhibitory action of NRIs on chemokines and CAM expression was mimicked by in vitro exposure of cultured glial cells to noradrenaline, but not to the NRIs themselves. These data indicate that the suppressive action of NRIs on chemokine and CAM expression that occurs in vivo is due to increased noradrenaline availability at glial cells, as opposed to a direct action of the drugs on glial cells per se. These results support the theory that noradrenaline has anti-inflammatory properties, and agents that increase noradrenaline availability in vivo can play a role in combating brain inflammation by reducing expression of chemokines and CAMs; molecules that facilitate leucocyte influx into the CNS. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061033     DOI: 10.1016/j.jneuroim.2009.12.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

1.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

2.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

3.  Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders.

Authors:  Demian Obregon; Ellisa Carla Parker-Athill; Jun Tan; Tanya Murphy
Journal:  Neuropsychiatry (London)       Date:  2012-08

4.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

Review 5.  Noradrenergic Modulation on Dopaminergic Neurons.

Authors:  Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2018-03-23       Impact factor: 3.911

Review 6.  The role of the gut-brain axis in alcohol use disorders.

Authors:  Jonathan Gorky; James Schwaber
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-07-16       Impact factor: 5.067

Review 7.  Central Noradrenergic Agonists in the Treatment of Ischemic Stroke-an Overview.

Authors:  Zohi Sternberg; B Schaller
Journal:  Transl Stroke Res       Date:  2019-07-20       Impact factor: 6.829

8.  Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults.

Authors:  Linda L Carpenter; Cyrena E Gawuga; Audrey R Tyrka; Janet K Lee; George M Anderson; Lawrence H Price
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

9.  Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction.

Authors:  Silvia Di Prisco; Elisa Merega; Massimiliano Lanfranco; Simona Casazza; Antonio Uccelli; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

10.  Development of amyloid burden in African Green monkeys.

Authors:  Sergey Kalinin; Stephanie L Willard; Carol A Shively; Jay R Kaplan; Thomas C Register; Matthew J Jorgensen; Paul E Polak; Israel Rubinstein; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2013-04-18       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.